质子治疗降低食管癌同步放化疗急性血液学毒性的潜力
PURPOSE: Radiation therapy dose escalation using a simultaneous integrated boost (SIB) is predicted to improve local tumor control in esophageal cancer; however, any increase in acute hematologic toxicity (HT) could limit the predicted improvement in patient outcomes.…
要点
- 质子治疗可显著降低骨V10Gy和骨平均剂量。
- 3D50计划骨平均剂量和TV V30Gy最高。
- VMAT计划骨V10Gy高于3D50计划。
核心结论
- 质子治疗可降低食管癌同步放化疗患者的骨髓毒性。
主要发现
- 3D50计划骨平均剂量和TV V30Gy最高。
- VMAT计划骨V10Gy高于3D50计划。
- 再优化VMAT62.5计划改善了TV保护,但仅质子计划显著降低骨V10Gy和骨平均剂量,尤其大PTV患者。
关键数值与推荐
- VMAT SIB计划高危亚区处方剂量为62.5 Gy。
临床怎么用
- 对于食管癌同步放化疗患者,可考虑质子治疗以减少骨髓受照剂量,尤其在大PTV患者中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation therapy dose escalation using a simultaneous integrated boost (SIB) is predicted to improve local tumor control in esophageal cancer; however, any increase in acute hematologic toxicity (HT) could limit the predicted improvement in patient outcomes. Proton therapy has been shown to significantly reduce HT in lung cancer patients receiving concurrent chemotherapy. Therefore, we investigated the potential of bone marrow sparing with protons for esophageal tumors. METHODS AND MATERIALS: Twenty-one patients with mid-esophageal cancer who had undergone conformal radiation therapy (3D50) were selected. Two surrogates for bone marrow were created by outlining the thoracic bones (bone) and only the body of the thoracic vertebrae (TV) in Eclipse. The percentage of overlap of the TV with the planning treatment volume was recorded for each patient. Additional plans were created retrospectively, including a volumetric modulated arc therapy (VMAT) plan with the same dose as for 3D50; a VMAT SIB plan with a dose prescription of 62.5 Gy to the high-risk subregion within the planning treatment volume; a reoptimized TV-sparing VMAT plan; and a proton therapy plan with the same SIB dose prescription. The bone and TV dose metrics were recorded and compared across all plans and variations with respect to PTV and percentage of overlap for each patient. RESULTS: The 3D50 plans showed the highest bone mean dose and TV percentage of volume receiving ≥30 Gy (V30Gy) for each patient. The VMAT plans irradiated a larger bone V10Gy than did the 3D50 plans. The reoptimized VMAT62.5 VT plans showed improved sparing of the TV volume, but only the proton plans showed significant sparing for bone V10Gy and bone mean dose, especially for patients with a larger PTV. CONCLUSIONS: The results of the present study have shown that proton therapy can reduced bone marrow toxicity.
引用
- Warren S, Hurt CN, Crosby T, et al. Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 29280467. doi:10.1016/j.ijrobp.2017.07.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。